Report description

Technological innovations in the medical device industry have led to a radical transformation in patient care. This report identifies the sectors with the industry’s most important developments related to patient care, clinical outcomes, and new product development. While the scope of the report is limited to the top ten technologies only, it covers almost the entire medical device market.

Scientific and medical technology breakthroughs – such as minimally invasive surgery (MIS) – have accelerated the accuracy of clinical outcomes and have also reduced recovery times and the medical costs borne by patients. This has led to radical transformation in patient care.

IT integration in medical imaging and medical devices has given a significant boost to the healthcare industry, a trend that is apparent in the market growth of drug eluting stents and telemedicine technologies. The markets covered in the report have a current potential of $454.3 billion and are expected to grow at a CAGR of 9.8% between 2009 and 2014.

Market estimates and forecast
The report provides in-depth market estimates and forecast for top ten medical device technologies as follows:
• Diagnostic imaging (nuclear imaging, interventional radiology, capsule endoscopy and others)
• Drug delivery (needle free injections, transdermal systems, inhalation system, infusion system)
• Molecular diagnostics (biosensors, proteomics, nanotechnology, and others)
• Mobility aid technologies
• Minimal/non-invasive surgery (stents, bariatric surgery, medical robotics and others)
• Micro-fluids and MEMS (Miniature medical pressure sensors, bio chips, protein chips)
• Non-invasive monitoring (continuous blood glucose monitoring)
• Biomaterials (bionic limbs, joint replacement, antimicrobial wound dressing and others)
• Bio-implants (neurostimulation and others)
• Tele-medicines

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments.


What makes our reports unique?
• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.
• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW.
• We provide 10% customization - Research shows that more than 40% of the times, clients do not get the specific intelligence they need in multi-client market research reports. We offer 10% customization in our reports at no extra cost. Get the exact market intelligence you require with real value for money.
• 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and Analysis
The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

 

TABLE OF CONTENTS
1. INTRODUCTION
1.1. KEY TAKE AWAYS
1.2. REPORT DESCRIPTION
1.3. MARKETS COVERED
1.4. STAKEHOLDERS
1.4.1.MEDICAL DEVICE MANUFACTURERS
1.4.2.HOSPITAL SURGICAL DEPARTMENTS
1.4.3.CLINICAL RESEARCH FIRMS
1.4.4.BUSINESS RESEARCH AND CONSULTING SERVICE PROVIDERS
2. SUMMARY
3. MARKET OVERVIEW
3.1. COMPARATIVE ANALYSIS OF THE TOP TEN MEDICAL DEVICE TECHNOLOGIES
3.2. EVOLUTION OF MEDICAL DEVICE TECHNOLOGIES
3.3. DEFINING THE TOP TEN MEDICAL DEVICE TECHNOLOGIES MARKET
3.4. PHYSICIANS ADOPTING INNOVATIVE TECHNOLOGIES
3.5. AGING POPULATION DRIVES THE MARKET
3.5.1. OPPORTUNITY LIES IN LESS DEVELOPED COUNTRIES
3.6. SYNERGY BETWEEN TECHNOLOGIES GIVES BETTER OUTCOMES
3.7. PRODUCT RECALLS ARE A MAJOR CHALLENGE
4. DIAGNOSTIC IMAGING
4.1. DRIVERS
4.1.1. EMERGENCE OF NEW TECHNOLOGY
4.1.2. WIDE APPLICATION AREAS
4.1.3. AGING DEMOGRAPHICS
4.1.4. FOCUS ON PREVENTIVE HEALTHCARE
4.1.5. CMS COVERS MORE TESTS
4.2. RESTRAINTS
4.2.1. ECONOMIC SLOWDOWN
4.2.2. REGULATORY BODIES RAISE HEALTHCARE COSTS
4.3. COMPETITIVE LANDSCAPE
4.4. MRI SYSTEMS
4.4.1. DRIVERS
4.4.1.1. Wide Range of Applications
4.4.1.2. Improvement in Telsa Strength
4.4.2. COMPETITIVE LANDSCAPE
4.5. ULTRASOUND SYSTEMS
4.5.1. DRIVERS
4.5.1.1.Untapped Demand in Emerging Markets
4.5.1.2.Booming Refurbished Equipment Market for Ultrasound Systems
4.5.1.3.Increased Use of Ultrasound by EMS
4.5.2. RESTRAINTS
4.5.2.1. Saturation in Core Markets
4.5.2.2. Lack of Clear Reimbursement Policies
4.5.3. COMPETITIVE LANDSCAPE
4.6. X-RAY SYSTEMS
4.6.1. DRIVERS
4.6.1.1. Fine Image Quality
4.6.2. RESTRAINTS
4.6.2.1. Other advanced technologies hindering growth of X-ray market
4.6.2.2. High degree of Competition
4.6.3. COMPETITIVE LANDSCAPE
4.6.3.1. Mergers and Acquisitions
4.6.3.2. New X-ray Systems
4.7. MAMMOGRAPHY EQUIPMENT
4.7.1. DRIVERS
4.7.1.1. Increase in Demand
4.7.1.2. Favorable Reimbursement Scenario
4.8. TOMOGRAPHY EQUIPMENT
4.8.1. DRIVERS
4.8.1.1. Introduction of Higher Slice CT Scanner
4.8.1.2. Increase in Angiogram CT Application
4.8.1.3. Introduction of OCT
4.8.2. RESTRAINTS
4.8.2.1. Shift from a Slice Count Basis to Detector Coverage
4.8.2.2. MRI Moving Ahead of CT Scan
4.8.3. COMPETITIVE DEVELOPMENT
4.9. NUCLEAR IMAGING EQUIPMENT
4.9.1. COMPETITIVE LANDSCAPE
4.9.1.1. Other Developments
4.10. INTERVENTIONAL RADIOLOGY
4.10.1. DRIVERS
4.10.1.1. Advances in Medical Instrumentation and Radiological Imaging Technology
4.10.1.2. Minimally Invasive Imaging Procedures Gaining Popularity
4.10.2. RESTRAINTS
4.10.2.1. Financial Limitation Hinders Capital Investment
4.10.2.2. Lack of Professional Radiologists
4.11. CAPSULE ENDOSCOPY
4.11.1. DRIVERS
4.11.1.1. Increased Application of Capsule Endoscopy
4.11.1.2. FDA Clearances
4.11.2. COMPETITIVE LANDSCAPE
4.12. LASERS – IMAGING
4.12.1. DRIVERS
4.12.1.1. Reasonable Pricing
4.12.1.2. Expansion of scope and opportunities for laser technology
5. DRUG DELIVERY DEVICES
5.1. INHALATION SYSTEMS
5.2. COMPETITIVE LANDSCAPE
5.3. INFUSION SYSTEMS
5.3.1. COMPETITIVE LANDSCAPE
5.4. NEEDLE-FREE INJECTION/TRANSDERMAL SYSTEMS
5.4.1. DRIVERS
5.5. INCREASE IN INCIDENCE OF ARTHRITIS AND HORMONE DEFICIENCY
5.6. OTHER DEVELOPMENTS IN NEEDLE-FREE INJECTION/TRANSDERMAL SYSTEMS MARKET
6. MEDICAL DIAGNOSTICS
6.1. DRIVERS
6.1.1. POPULARITY OF HOME HEALTHCARE 66
6.1.2. DEMAND FOR GENETIC, MOLECULAR DIAGNOSTIC TESTING
6.2. RESTRAINTS
6.2.1. ECONOMIC SLOWDOWN AND INSURANCE ISSUES
6.3. BIOSENSORS
6.3.1. DRIVERS
6.3.1.1. Increase in Biosensor Usage Due To Multiple Applications
6.3.1.2. Unhealthy Lifestyles
6.3.1.3. Miniaturization Key to Success of Biosensors
6.3.2. RESTRAINTS
6.3.2.1. High R&D costs
6.4. IN VITRO DIAGNOSTIC (IVD)
6.4.1. DRIVERS
6.4.1.1. Demand for IVD in Emerging Markets
6.4.1.2. Increasing Need For Diagnostic Services
6.4.1.3. Increasing Accessibility of Healthcare Services
6.4.2. RESTRAINTS
6.4.2.1. Consolidation of Hospital and Commercial Laboratories
6.4.2.2. Intense FDA Scrutiny on IVD Diagnostic Market
6.5. PROTEOMICS FOR MEDICAL DIAGNOSTICS
6.5.1. DRIVERS
6.5.1.1. Proteomics Targeting More Diseases
6.5.1.2. Enables Pharmacological Profiling, Toxicity Testing
6.5.1.3. Detection of Non-communicable Diseases
6.5.2. RESTRAINTS
6.5.2.1. Protein Structuring Needs Expensive Instrumentation
6.5.2.2. Cost and Reimbursement Issues
6.5.2.3. Lack of Technologies to Speed up Validation Process
6.6. NANOTECHNOLOGY FOR MEDICAL DIAGNOSTICS
6.6.1. DRIVERS
6.6.1.1. Increase in Demand for Genetic & Preimplantation Screening
6.6.2. OPPORTUNITY
6.6.2.1. Nanotechnology for Cancer Diagnostics
6.6.3. RESTRAINT
6.6.3.1. Lack of Commercialization
6.6.3.2. Other Developments
6.7. POLYMERASE CHAIN REACTION (PCR)
6.7.1. DRIVERS
6.7.1.1. Potential to Replace Conventional Tests for Diseases
6.7.1.2. FDA Clearance for Real-Time PCR Instrumentation
6.7.2. RESTRAINTS
6.7.2.1. qPCR Technology Replacing Conventional PCR
6.7.2.2. Price sensitivity of PCR technology
6.8. ARRAYS
6.8.1. DRIVERS
6.8.1.1. Demand for Protein Array on Rise
6.8.1.2. Micro Array Technology Classifies Cancers
6.8.1.3. Minimal Use of Materials Makes Microarrays an Inexpensive Technology
7. MOBILITY AID TECHNOLOGIES
7.1. DRIVERS
7.1.1. POPULATION WITH MOBILITY ISSUES 81
7.1.2. SPORTS FOR PHYSICALLY CHALLENGED GAINING POPULARITY
7.1.3. EMERGENCE OF ROBOTICS TECHNOLOGY
7.2. COMPETITIVE LANDSCAPE
7.3. GLOBAL MOBILITY AID TECHNOLOGIES MARKET BY PRODUCTS
7.3.1. WHEELCHAIRS AND RELATED DEVICES
7.3.1.1. Drivers
7.3.1.1.1. Wide Range of Designs, Materials, and Configurations
7.3.1.1.2. Increase in Demand for Power Wheelchair
7.3.1.2. Restraints
7.3.1.2.1. Power Dependence
7.3.1.2.2. Powered Assist Devices are Costly and Less Portable
7.3.1.2.3. Reimbursement Issues with Powered Wheelchairs
7.3.1.3. Competitive Landscape
7.3.2. WALKING-ASSIST DEVICES
7.4. GLOBAL MOBILITY AID DEVICE MARKET BY TECHNOLOGY
7.4.1. ROBOTICS
7.4.2. NON-ROBOTICS
8. MINIMAL INVASIVE/NON-INVASIVE SURGERY
8.1. DRIVERS
8.1.1. LESS PAINFUL AND SHORT CONVALESCENCE
8.1.2. INCREASED NEED OF SURGERIES FOR THE ELDERLY
8.1.3. HIGHER RATE OF ACCEPTANCE
8.2. RESTRAINTS
8.2.1. LIMITED NUMBER OF SURGERIES PERFORMED
8.2.2. SPECIAL TRAINING AND EQUIPMENT REQUIRED
8.3. OPPORTUNITIES
8.3.1. HUGE MARKET SIZE
8.4. STENT
8.4.1. DRIVERS
8.4.1.1. Rise in Cardiovascular Diseases
8.4.1.2. Increasing Incidence of Obesity and Diabetes
8.5. MEDICAL ROBOTICS
8.5.1. DRIVERS
8.5.1.1. Improved Surgical Results
8.5.1.2. Hospitals encourage medical robots
8.5.1.3. Cost effectiveness
8.5.2. COMPETITIVE LANDSCAPE
8.6. LASERS
8.6.1. DRIVERS
8.6.1.1. Growing Awareness
8.6.1.2. Rise in Age-Related Diseases
8.6.2. DEVELOPMENTS
8.7. BARIATRIC SURGERY
8.7.1. DRIVERS
8.7.1.1. Increasing Incidence of Weight Problems
8.7.1.2. Technological Innovation
8.7.1.3. Rising Obesity among Children
9. MICRO- FLUIDS CHIP AND MEMS
9.1. DRIVERS
9.1.1. COST-EFFECTIVE COMPLEX ANALYSIS SYSTEM
9.1.2. ESSENTIAL TOOL FOR MASS SPECTROMETRY
9.1.3. COMPLETE AUTOMATION IN A SINGLE DEVICE
9.1.4. GREATER SPEED & HIGHER QUALITY
9.1.5. MINIMAL REQUIREMENT OF SAMPLES REDUCES COST
9.2. RESTRAINTS
9.2.1. MICROFLUIDIC CHIP TECHNOLOGY CANNOT MIX FLUIDS
9.2.2. LACK OF COMMERCIALIZATION
9.3. MINIATURE MEDICAL PRESSURE SENSORS
9.4. BIOCHIPS
9.4.1. DRIVERS AND RESTRAINTS
9.4.1.1. Application of biochips in personalized medicine
9.4.1.2. Biochips help save time
9.4.1.3. Biochips aid new drug discovery
9.4.1.4. High cost associated with biochips
9.5. COMPETITIVE LANDSCAPE
9.5.1. Other developments
9.5.1.1. DNA CHIPS
9.5.2. LAB CHIPS
9.5.3. PROTEIN CHIPS
9.5.3.1. Developments
10.NON-INVASIVE MONITORING
10.1.BIOSENSORS
10.1.1. WIDE SCALE ACCEPTABILITY OF BIOSENSORS
10.1.2. HIGH COST INVOLVED IN COMMERCIALIZATION
10.1.3. CONTINUOUS GLUCOSE MONITORING
10.1.3.1. Drivers
10.1.3.1.1. Increasing incidence of diabetes
10.1.3.1.2. Convenience of non-invasive continuous glucose monitoring
11.BIOMATERIALS
11.1.INCREASE IN ORTHOPEDIC PROBLEMS
11.2.HIGH DEGREE OF REGULATORY SCRUTINY
11.3.APPLICATIONS OF BIOMATERIALS
11.4.BIONIC LIMBS
11.4.1. COMPETITIVE LANDSCAPE
11.5.BIO-COMPATIBLE MATERIALS
11.5.1. DRIVERS
11.5.1.1. Advancements in nanotechnology
11.5.1.2. Increase in demand of bio-compatible materials
11.5.2. VULCANIZED SILICON-BASED MATERIALS
11.5.3. JOINT REPLACEMENT
11.5.3.1. Drivers
11.5.3.1.1. Increasing acceptability of bone grafts substitutes
11.5.3.2. Restraints
11.5.3.2.1. Rise in prices of titanium
11.5.3.2.2. Modification in reimbursement policies
11.6.ANTIMICROBIAL WOUND DRESSING
11.6.1. DRIVERS
11.6.1.1.1. New products in anti-microbial wound dressing
11.6.1.1.2. Increasing demand in the home healthcare sector
12.BIO-IMPLANTS
12.1.GRAFT-BASED IMPLANTS
12.1.1. DRIVERS
12.1.1.1. Increasing medical acceptance of graft-based implants
12.1.1.2. Increasing popularity of cosmetic surgery
12.1.2. RESTRAINTS
12.1.2.1. Expensive bone grafts
12.2.SYNTHETIC IMPLANTS
12.2.1. DRIVERS
12.2.1.1. Wide range of applications
12.2.1.2. Synthetic implants are bio-compatible
12.2.2. NEUROSTIMULATION
12.2.2.1. Drivers
12.2.2.1.1. Increase in neurological disorders
12.2.2.1.2. Increase in demand for less complicated operating methods
12.2.2.1.3. Short treatment period
12.2.2.1.4. Technological advancements
12.2.2.2.5 The use of implantable neurostimulation devices
12.2.2.2. Opportunities
12.2.2.2.1. Wide range of innovative therapies
12.2.2.2.2. Huge market size encourages market growth
12.2.2.3. Spinal Cord Stimulation (SCS)
12.2.2.3.1. Drivers
12.2.2.3.1.1. Wide range of applications of spinal cord devices
12.2.2.3.1.2. New improved technology in spinal cord stimulator devices
12.2.2.3.2. Opportunities
12.2.2.3.2.1. FDA approval for spinal cord stimulator devices
12.2.2.4. Developments
12.2.2.5. Sacral Nerve Stimulation (SNS)
12.2.2.5.1. Drivers
12.2.2.5.1.1. Rise in number of patients
12.2.2.5.1.2. Sacral stimulation treatments facilitate increased surgical accuracy
12.2.2.5.2. Opportunities
12.2.2.5.2.1. Huge potential in Asian countries
12.2.2.6. Vagus Nerve Stimulation (VNS)
12.2.2.6.1. Drivers
12.2.2.6.1.1. Effective treatment for partial–onset seizures
12.2.2.6.2. Opportunities
12.2.2.6.2.1. Developments for VNS Market
12.2.2.6.2.2. Regulatory Approval for VNS Market
12.2.2.7. Deep Brain Stimulation Systems
12.2.2.7.1. Drivers
12.2.2.7.1.1. Improved treatments results attracting more patients
12.2.2.7.1.2. New and advanced technology provides greater flexibility to neurosurgeons
12.2.2.7.2. Restraints and Opportunities
12.2.2.7.3. Competitive Landscape
13.TELEMEDICINE
13.1.DRIVERS
13.1.1. INCREASE IN INCIDENCE OF CHRONIC DISEASES
13.1.2. COMPLEXITY OF HEALTHCARE NETWORK
13.1.3. INCREASED IT EXPENDITURE
13.1.4. SHIFTING TREND FROM TREATMENT TO EARLY INTERVENTION
13.2.RESTRAINTS
13.2.1. UNCERTAIN REIMBURSEMENT FOR TELEMEDICINE
13.2.2. LACK OF FUNDING FOR TELEMEDICINE PROGRAMS
13.2.3. TELEMEDICINE TECHNOLOGY
13.2.3.1. Hardware
13.2.3.2. Software
13.2.3.3. Network and Telecom
13.2.3.3.1. Telecom and networking market
13.2.3.3.2. Telehome T&N market
13.2.3.3.3. Telehospital/clinics T&N market
14.TOP TEN MEDICAL DEVICE TECHNOLOGIES PATENT ANALYSIS
14.1.GENERAL TRENDS
15.COMPANY PROFILES
15.1.ABBOTT LABORATORIES
15.1.1. OVERVIEW
15.1.2. DEVELOPMENTS
15.2.ATRIUM MEDICAL CORPORATION
15.2.1. OVERVIEW
15.2.2. DEVELOPMENTS
15.3.BOSTON SCIENTIFIC
15.3.1. OVERVIEW
15.3.2. DEVELOPMENTS
15.4.BERCHTOLD CORPORATION (SUBSIDIARY OF BERCHTOLD GMBH & CO. KG)
15.4.1. OVERVIEW & PRODUCTS
15.5.CONOR MEDSYSTEMS, LLC
15.5.1. OVERVIEW
15.5.2. DEVELOPMENTS
15.6.CELONOVA BIOSCIENCES INC
15.6.1. OVERVIEW
15.6.2. DEVELOPMENTS
15.7.ETHICON ENDO-SURGERY
15.7.1. OVERVIEW & DEVELOPMENTS
15.8.INTROMEDIC
15.8.1. OVERVIEW & PRODUCT
15.8.2. DEVELOPMENTS
15.9.HITACHI MEDICAL CORPORATION
15.9.1. OVERVIEW
15.9.2. DEVELOPMENTS
15.10.GIVEN IMAGING
15.10.1. OVERVIEW
15.10.2. DEVELOPMENTS
15.11. GE HEALTHCARE
15.11.1. OVERVIEW
15.11.2. DEVELOPMENTS
15.12.BIOMET, INC
15.12.1. OVERVIEW
15.12.2. DEVELOPMENTS
15.13.SIEMENS MEDICAL SOLUTIONS
15.13.1. OVERVIEW
15.13.2. DEVELOPMENTS
15.14.XTENT, INC.
15.14.1. OVERVIEW & PRODUCTS
15.15.VALLEYLAB
15.15.1. OVERVIEW
15.16.TERUMO MEDICAL CORPORATION
15.16.1. OVERVIEW
15.16.2. DEVELOPMENTS
15.17.MIV THERAPEUTICS, INC.
15.17.1. OVERVIEW
15.17.2. DEVELOPMENTS
15.18.ORBUSNEICH
15.18.1. OVERVIEW & DEVELOPMENTS
15.19.STENTYS S.A.S.
15.19.1. OVERVIEW & DEVELOPMENTS
15.20.MEDINOL LTD.
15.20.1. OVERVIEW
15.20.2. DEVELOPMENTS
15.21.PROSURGICS
15.21.1. OVERVIEW
15.21.2. DEVELOPMENTS
15.22.ROCHE
15.22.1. OVERVIEW
15.22.2. R&D INNOVATIONS
15.23.OLYMPUS
15.23.1. OVERVIEW
15.23.2. DEVELOPMENTS
15.24.MEDTRONIC, INC.
15.24.1. OVERVIEW
15.24.2. DEVELOPMENTS
15.25.SCIENTIFIC INTAKE CO LTD
15.26.SATIETY, INC
15.27.METACURE NV
15.28.LEPTOS BIOMEDICAL, INC.
15.29.SMITH & NEPHEW
15.29.1. OVERVIEW
15.29.2. DEVELOPMENTS
15.30.ENDOART SA
15.31.INTUITIVE SURGICAL, INC
15.31.1. PRODUCTS
15.31.2. DEVELOPMENTS
15.32.ALLERGAN
15.32.1. OVERVIEW
15.33.ENTEROMEDICS
15.33.1. OVERVIEW & PRODUCTS
15.34.HÉLIOSCOPIE SA
15.34.1. OVERVIEW
15.35.KARL-STORZ GMBH & CO. KG
15.35.1. RECENT DEVELOPMENTS
15.36.BARONOVA, INC.
15.36.1. OVERVIEW & PRODUCTS
15.37.ESAOTE SPA
15.37.1. OVERVIEW
15.37.2. DEVELOPMENTS
15.38.STRYKER
15.38.1. OVERVIEW
15.38.2. EVELOPMENTS
APPENDIX